Results 1 to 10 of about 260,498 (362)

HIV protease inhibitors: a review of molecular selectivity and toxicity [PDF]

open access: yesHIV/AIDS: Research and Palliative Care, 2015
Zhengtong Lv,* Yuan Chu,* Yong Wang Department of Immunology, School of Basic Medical Science, Xiangya School of Medicine, Central South University, Changsha, Hunan, People's Republic of China *Both authors contributed equally to this work ...
Lv Z, Chu Y, Wang Y
doaj   +3 more sources

Molecular Mechanisms of HIV Protease Inhibitors Against HPV-Associated Cervical Cancer: Restoration of TP53 Tumour Suppressor Activities [PDF]

open access: yesFrontiers in Molecular Biosciences, 2022
Cervical cancer is a Human Papilloma virus-related disease, which is on the rise in a number of countries, globally. Two essential oncogenes, E6 and E7, drive cell transformation and cancer development.
Lilian Makgoo   +2 more
doaj   +2 more sources

Developing HIV-1 Protease Inhibitors through Stereospecific Reactions in Protein Crystals [PDF]

open access: yesMolecules, 2016
Protease inhibitors are key components in the chemotherapy of HIV infection. However, the appearance of viral mutants routinely compromises their clinical efficacy, creating a constant need for new and more potent inhibitors.
Folasade M. Olajuyigbe   +3 more
doaj   +6 more sources

Susceptibility of HPV-18 Cancer Cells to HIV Protease Inhibitors [PDF]

open access: yesViruses
Cervical cancer cases continue to rise despite all the advanced screening and preventative measures put in place, which include human papillomavirus (HPV) vaccination.
Lilian Makgoo   +2 more
doaj   +2 more sources

Computational Simulation of HIV Protease Inhibitors to the Main Protease (Mpro) of SARS-CoV-2: Implications for COVID-19 Drugs Design [PDF]

open access: yesMolecules, 2021
SARS-CoV-2 is highly homologous to SARS-CoV. To date, the main protease (Mpro) of SARS-CoV-2 is regarded as an important drug target for the treatment of Coronavirus Disease 2019 (COVID-19). Some experiments confirmed that several HIV protease inhibitors
Wei Yu   +14 more
doaj   +2 more sources

HIV protease inhibitors restore amphotericin B activity against Candida. [PDF]

open access: yesPLoS ONE
Candida auris is an invasive fungal pathogen, representing a global public health threat. It is characterized by high mortality rates among infected individuals, significant antifungal resistance, and a remarkable ability to persist in healthcare ...
Yehia Elgammal   +2 more
doaj   +2 more sources

HIV Protease: Historical Perspective and Current Research

open access: yesViruses, 2021
The retroviral protease of human immunodeficiency virus (HIV) is an excellent target for antiviral inhibitors for treating HIV/AIDS. Despite the efficacy of therapy, current efforts to control the disease are undermined by the growing threat posed by ...
Irene T. Weber   +2 more
doaj   +1 more source

Drug Reprofiling to Identify Potential HIV-1 Protease Inhibitors

open access: yesMolecules, 2023
The use of protease inhibitors in human immunodeficiency virus type 1 (HIV-1) treatment is limited by adverse effects, including metabolic complications. To address these challenges, efforts are underway in the pursuit of more potent and less toxic HIV-1
Sunday N. Okafor   +7 more
doaj   +1 more source

Ultra-fast analysis of plasma and intracellular levels of HIV protease inhibitors in children: a clinical application of MALDI mass spectrometry. [PDF]

open access: yesPLoS ONE, 2010
HIV protease inhibitors must penetrate into cells to exert their action. Differences in the intracellular pharmacokinetics of these drugs may explain why some patients fail on therapy or suffer from drug toxicity.
Jeroen J A van Kampen   +10 more
doaj   +1 more source

Phenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in patients who are chronically infected with human immunodeficiency virus type 1 [PDF]

open access: yes, 2005
Increased susceptibility to the protease inhibitors saquinavir and amprenavir has been observed in human immunodeficiency virus type 1 (HIV-1) with specific mutations in protease (V82T and N88S).
Clotet, B   +7 more
core   +2 more sources

Home - About - Disclaimer - Privacy